Medidata Expands Partnership with The Menarini Group, Deploying Medidata's Study Build AI Technology to Accelerate Global Oncology Pipeline

Medidata announced an expansion of its 14-year partnership with The Menarini Group, specifically its oncology subsidiary Stemline Therapeutics, which will deploy Medidata's Study Build AI technology to accelerate clinical trial start-up. The system draws on data from over 38,000 trials to automate study configurations, and the page states this reduces startup time from months to weeks. Stemline had recently launched its first oncology study independently using Medidata's Data Experience platform, which the announcement cites as the basis for the expanded deployment.

Medidata is a Dassault Systèmes company supplying the clinical-trial EDC and data platform (Rave) most sponsors and CROs already run live trials on, now with an AI layer built in.

This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.